The clinical phase I tests, using an anti-Aß antibody developed by Kyowa Hakko Kirin subsidiary Oncotherapy, will be done in Belgium. They cover Alzheimer’s disease in a prodromal phase

Kyowa Hakko Kirin news release, June 19, 2104